LIFE240517P5000
- 3.80
- 0.000.00%
aTyr Pharma Newsroom
Analysts' Top Healthcare Picks: ATyr Pharma (LIFE), Dynavax (DVAX)
ATyr Pharma Says DSMB Recommended Ongoing Phase 3 EFZO-FIT Study Of Efzofitimod Continue Without Any Modifications
ATyr Pharma Says DSMB Recommended Ongoing Phase 3 EFZO-FIT Study Of Efzofitimod Continue Without Any Modifications
ATyr Pharma to Present at Upcoming Investor Conferences
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro
HC Wainwright & Co. : The ATyr Pharma (LIFE.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $35.00.
HC Wainwright & Co. : The ATyr Pharma (LIFE.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $35.00.
RBC Capital Sticks to Their Buy Rating for ATyr Pharma (LIFE)
Strong Buy Rating for ATyr Pharma as Efzofitimod Shows Promise and Financial Stability
ATyr Pharma Q1 EPS $(0.23) Beats $(0.24) Estimate, Sales $235.00K Beat $20.00K Estimate
aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 20.69 percent increase over losses of $(0.29) p
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000
04:00 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000
ATyr Pharma 1Q Loss/Shr 23c >LIFE
ATyr Pharma 1Q Loss/Shr 23c >LIFE
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersJaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $
ATyr Pharma to Participate in April Investor Conferences
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its p
WW, ATNM and XTIA Are Among Pre Market Gainers
Repligen Appoints Maggie A. Pax to Board of Directors
ATyr Pharma Full Year 2023 Earnings: Revenues Disappoint
ATyr Pharma Is Maintained at Outperform by RBC Capital
ATyr Pharma Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Outperform on ATyr Pharma, Lowers Price Target to $16
RBC Capital analyst Gregory Renza maintains aTyr Pharma (NASDAQ:LIFE) with a Outperform and lowers the price target from $19 to $16.
ATyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)
Buy Rating Affirmed for ATyr Pharma as Lead Candidate Efzofitimod Advances in Clinical Trials With Solid Financial Footing
Earnings Call Summary | ATyr Pharma(LIFE.US) Q4 2023 Earnings Conference
The following is a summary of the ATyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript:Financial Performance:ATyr Pharma ended 2023 with $101.7 million in cash, restricted cash, cash equivalents,